Welcome to our dedicated page for Kailera Therapeutics news (Ticker: KLRA), a resource for investors and traders seeking the latest updates and insights on Kailera Therapeutics stock.
Kailera Therapeutics reports company developments tied to its transition into the public markets and its clinical-stage obesity therapeutics business. News items cover the pricing and closing of its initial public offering, the listing of KLRA common stock on the Nasdaq Global Select Market, and equity financing associated with its development-stage operations.
Company updates also frame Kailera as an advanced clinical-stage biotechnology issuer focused on obesity care, with public communications centered on capital formation, listing status, and product-candidate development in GLP-1 based obesity therapeutics.
Kailera Therapeutics (NASDAQ:KLRA) and Hengrui Pharma will present new clinical data on ribupatide at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026, in New Orleans.
Posters cover Phase 2 oral ribupatide in obesity and a Phase 1 single-ascending dose study of injectable KAI-9531.
Hengrui Pharma (KLRA) reported Q1 2026 revenue of RMB 8.14 billion, up 12.98% YoY, and net profit attributable to shareholders of RMB 2.28 billion, up 21.78% YoY. Innovative drugs generated RMB 4.53 billion, up 25.75% YoY and 61.69% of pharmaceutical sales.
R&D spending was RMB 2.22 billion (~27.32% of revenue). The company recognized RMB 787 million in out-licensing revenue and recorded pipeline progress: 26 clinical trial approvals and 8 NDAs accepted in China. Kailera Therapeutics (NASDAQ: KLRA) completed a Nasdaq listing as a NewCo for GLP-1 assets.
Kailera (Nasdaq: KLRA) closed its initial public offering on April 20, 2026, selling 44,921,875 common shares at $16.00 per share, including full exercise of the underwriters' option for 5,859,375 additional shares.
The aggregate gross proceeds were $718.8 million before underwriting discounts, commissions and offering expenses; Kailera's common stock is listed on the Nasdaq Global Select Market under the ticker KLRA.
Kailera Therapeutics (Nasdaq: KLRA) priced an initial public offering of 39,062,500 shares at $16.00 per share, implying gross proceeds of approximately $625.0 million. Shares are expected to begin trading on the Nasdaq Global Select Market under KLRA on April 17, 2026, with the offering expected to close April 20, 2026. The company granted underwriters a 30-day option to purchase up to 5,859,375 additional shares. Joint book-runners include J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI.